Medigen Biotechnology Corp. (TPEX:3176)
Taiwan · Delayed Price · Currency is TWD 31.70
-0.45 (-1.40%)
Feb 11, 2026, 1:30 PM CST
Medigen Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 1,586 | 1,373 | 1,158 | 1,056 | 3,922 | 615.54 | |
Revenue Growth (YoY) | 12.27% | 18.57% | 9.64% | -73.08% | 537.16% | 11.44% |
Cost of Revenue | 704.01 | 618.94 | 540.39 | 968.49 | 1,371 | 351.89 |
Gross Profit | 882.46 | 753.76 | 617.33 | 87.46 | 2,551 | 263.65 |
Selling, General & Admin | 556.44 | 571.21 | 499.64 | 402.31 | 376.61 | 341.3 |
Research & Development | 325.41 | 393.27 | 1,336 | 1,331 | 1,407 | 836.32 |
Other Operating Expenses | 48.57 | - | - | - | -1.36 | 1.36 |
Operating Expenses | 933.97 | 970.95 | 1,850 | 1,754 | 1,771 | 1,176 |
Operating Income | -51.51 | -217.2 | -1,233 | -1,667 | 779.96 | -912.32 |
Interest Expense | -23.27 | -36.39 | -55.86 | -39.45 | -19.07 | -31.88 |
Interest & Investment Income | 38.11 | 52.4 | 89.07 | 8.88 | 3.16 | 2.27 |
Earnings From Equity Investments | -30.13 | -28.44 | -92.26 | -262.21 | -98.8 | -54.57 |
Currency Exchange Gain (Loss) | -15.8 | 43.22 | -0.13 | 29.49 | 3.39 | 5 |
Other Non Operating Income (Expenses) | 10.15 | 5.24 | 24.03 | 74.31 | 457.12 | 90.99 |
EBT Excluding Unusual Items | -72.44 | -181.17 | -1,268 | -1,856 | 1,126 | -900.51 |
Gain (Loss) on Sale of Investments | -2.94 | -1.52 | -9.58 | -16.66 | 10.92 | -2.42 |
Gain (Loss) on Sale of Assets | -9.02 | 69.27 | -1.03 | - | -0.25 | 19.95 |
Other Unusual Items | 0.01 | 0.7 | - | 0 | - | 2.97 |
Pretax Income | -84.38 | -112.72 | -1,279 | -1,873 | 1,136 | -880.01 |
Income Tax Expense | 106.29 | 109.67 | 191.21 | 58.87 | 65.73 | -32.63 |
Earnings From Continuing Operations | -190.68 | -222.39 | -1,470 | -1,931 | 1,071 | -847.37 |
Net Income to Company | -190.68 | -222.39 | -1,470 | -1,931 | 1,071 | -847.37 |
Minority Interest in Earnings | 84.72 | 17.7 | 908.77 | 1,256 | -1,123 | 509.45 |
Net Income | -105.96 | -204.69 | -561.3 | -675.87 | -52.61 | -337.92 |
Net Income to Common | -105.96 | -204.69 | -561.3 | -675.87 | -52.61 | -337.92 |
Shares Outstanding (Basic) | 139 | 139 | 139 | 139 | 139 | 139 |
Shares Outstanding (Diluted) | 139 | 139 | 139 | 139 | 139 | 139 |
Shares Change (YoY) | -0.12% | -0.03% | 0.16% | 0.11% | -0.01% | 0.22% |
EPS (Basic) | -0.76 | -1.47 | -4.03 | -4.86 | -0.38 | -2.43 |
EPS (Diluted) | -0.76 | -1.47 | -4.03 | -4.86 | -0.38 | -2.43 |
Free Cash Flow | -11.15 | -16.93 | -541.93 | -1,286 | 375.16 | -820.23 |
Free Cash Flow Per Share | -0.08 | -0.12 | -3.89 | -9.25 | 2.70 | -5.90 |
Gross Margin | 55.62% | 54.91% | 53.32% | 8.28% | 65.05% | 42.83% |
Operating Margin | -3.25% | -15.82% | -106.51% | -157.87% | 19.89% | -148.21% |
Profit Margin | -6.68% | -14.91% | -48.48% | -64.01% | -1.34% | -54.90% |
Free Cash Flow Margin | -0.70% | -1.23% | -46.81% | -121.82% | 9.57% | -133.25% |
EBITDA | 96.49 | -66.3 | -1,078 | -1,498 | 967.36 | -711.59 |
EBITDA Margin | 6.08% | -4.83% | -93.11% | -141.83% | 24.66% | -115.60% |
D&A For EBITDA | 148 | 150.9 | 155.15 | 169.35 | 187.4 | 200.73 |
EBIT | -51.51 | -217.2 | -1,233 | -1,667 | 779.96 | -912.32 |
EBIT Margin | -3.25% | -15.82% | -106.51% | -157.87% | 19.89% | -148.21% |
Effective Tax Rate | - | - | - | - | 5.78% | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.